SUN PHARMACEUTICAL INDUSTRIES LTD.
NSE : SUNPHARMABSE : 524715ISIN
CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse
: Sun Pharma
BSE1508.40-10 (-0.66 % )
PREV CLOSE (Rs.) 1518.40
OPEN PRICE (Rs.) 1521.40
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 65933
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1511.15 -7.85 (-0.52 % )
PREV CLOSE(Rs.) 1519.00
OPEN PRICE (Rs.) 1527.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1511.15 (1401 )
VOLUME 3183226
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 04-May-2024 | Sun Pharmaceutical Industries informs about acquisition | <div style="text-align: justify;">Sun Pharmaceutical Industries has informed that Sun Pharmaceutical Industries (together with its subsidiaries and/or affiliates referred to as Sun Pharma), has entered into an agreement, pursuant to which Sun Pharma, through its wholly owned subsidiary, has agreed to acquire 100% shares of Valstar S.A. (Valstar). Further, Kemipharm S.A. (Kemipharm) is a subsidiary of Valstar and as a result of acquisition of Valstar and other minority shareholders, Sun Pharma would acquire entire stake in Kemipharm. The particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III are provided in Annexure A, enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 25-Apr-2024 | Pharma stocks jump amid rise in India's drugs and pharmaceuticals exports in FY24 | <p style="text-align: justify;">Stocks related to pharmaceuticals industry were trading higher on the BSE, as the commerce ministry in its latest data has showed that the country's drugs and pharmaceuticals exports increased 9.67 per cent year-on-year to $27.9 billion in 2023-24, even as the total exports dipped by 3 per cent in the last fiscal. In March 2024, pharma exports grew by 12.73 per cent to $2.8 billion.</p><p style="text-align: justify;">Sun Pharmaceutical Industries is currently trading at Rs. 1499.25, up by 12.90 points or 0.87% from its previous closing of Rs. 1486.35 on the BSE.</p><p style="text-align: justify;">Lupin is currently trading at Rs. 1593.00, up by 12.95 points or 0.82% from its previous closing of Rs. 1580.05 on the BSE.</p><p style="text-align: justify;">Aurobindo Pharma is currently trading at Rs. 1089.65, up by 6.05 points or 0.56% from its previous closing of Rs. 1083.60 on the BSE.</p><p style="text-align: justify;">According to the data, the top five export markets, for the sector during the last fiscal, are the US, the UK, the Netherlands, South Africa and Brazil. The US accounts for over 31 per cent of India's total pharma exports, followed by the UK and Netherlands (about 3 per cent each). In 2023-24, the outbound shipments also entered new geographies like Montenegro, South Sudan, Chad, Comoros, Brunei, Latvia, Ireland, Chad, Sweden, Haiti and Ethiopia.</p><p style="text-align: justify;">India's pharmaceutical industry is the third largest by volume and the 13th largest by value in the world, producing more than 60,000 generic drugs across 60 therapeutic categories. The government has rolled out two production-linked incentive (PLI) schemes to promote domestic manufacturing of key pharmaceutical ingredients and generic medicines. </p><div style="text-align: justify;"><br></div> |
| 12-Apr-2024 | USFDA issues OAI status to Sun Pharmaceutical Industries' Dadra facility | <p style="text-align: justify;">US Food and Drug Administration (USFDA) has issued Official Action Indicated (OAI) status to Sun Pharmaceutical Industries' Dadra facility. USFDA conducted an inspection at Company's Dadra facility from December 4, 2023 to December 15, 2023. The company will work with the regulator to achieve fully compliant status. </p><p style="text-align: justify;">Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.</p> |
| 28-Mar-2024 | Clarification sought from Sun Pharmaceutical Industries Ltd | The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on March 28, 2024, with reference to Movement in Volume. The reply is awaited. |
| 23-Mar-2024 | Sun Pharmaceutical Industries informs about details of loss of certificate | <div style="text-align: justify;">Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharmaceutical Industries has informed about details of loss of share certificate reported by shareholder of the Company. Name of the Shareholder: Hasmukh Bhai Patel, Folio No 008048. The Company will duly issue letter of confirmations in lieu of original share certificate.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 19-Mar-2024 | Sun Pharmaceutical Industries informs about press release | <div style="text-align: justify;">Sun Pharmaceutical Industries has informed that it enclosed a copy of the Press Release relating to Australian Therapeutic Goods Administration (TGA) approval for Winlevi®, which shall be released after this intimation.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE. </div><div><br></div> |
| 16-Mar-2024 | Sun Pharmaceutical Industries informs about loss of share certificate | <div style="text-align: justify;">Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharmaceutical Industries has informed that it enclosed the details of loss of share certificate reported by shareholder of the Company. The Company will duly issue letter of confirmation in lieu of original share certificate.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </div> |
| 14-Mar-2024 | Sun Pharmaceutical Industries informs about investor presentation | <div>Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharmaceutical Industries has informed that it enclosed the investor presentation, which shall be uploading on its website.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 11-Mar-2024 | Sun Pharma's arm recalls around 55,000 bottles of generic drug from US market | <p style="text-align: justify;">Sun Pharmaceutical Industries' subsidiary -- Sun Pharmaceutical Industries Inc.is recalling around 55,000 bottles of a generic medication to treat gout from the American market due to manufacturing practices norms deviations. The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths.<br>Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) respectively of the medication due to Current Good Manufacturing Practice regulations (CGMP) deviations.</p><p style="text-align: justify;">The affected lot was produced at Sun Pharma's Dadra-based plant for Memphis-based Northstar Rx LLC. Febuxostat is used to lower uric acid levels in people with gout. As per the US Food and Drug Administration (USFDA), a class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. </p><p style="text-align: justify;">Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.</p> |
| 11-Mar-2024 | Sun Pharma trades higher on the BSE | <p style="text-align: justify;">Sun Pharmaceutical Industries is currently trading at Rs. 1619.60, up by 12.95 points or 0.81% from its previous closing of Rs. 1606.65 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1608.45 and has touched a high and low of Rs. 1627.00 and Rs. 1600.00 respectively. So far 193787 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,627.00 on 11-Mar-2024 and a 52 week low of Rs. 922.55 on 22-May-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1,627.00 and Rs. 1528.35 respectively. The current market cap of the company is Rs. 388692.27 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.59% and 8.92% respectively.</p><p style="text-align: justify;">Sun Pharmaceutical Industries' subsidiary -- Sun Pharmaceutical Industries Inc.is recalling around 55,000 bottles of a generic medication to treat gout from the American market due to manufacturing practices norms deviations. The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths.</p><p style="text-align: justify;">Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) respectively of the medication due to Current Good Manufacturing Practice regulations (CGMP) deviations.</p><p style="text-align: justify;">The affected lot was produced at Sun Pharma's Dadra-based plant for Memphis-based Northstar Rx LLC. Febuxostat is used to lower uric acid levels in people with gout. As per the US Food and Drug Administration (USFDA), a class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. </p><p style="text-align: justify;">Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.</p><div style="text-align: justify;"><br></div> |
